title: Coley's toxins in perspective.
abstract: Despite initial hopes, the efficacy of tumour necrosis factor in treating cancer patients has been disappointing. But a more careful selection of patients, and more appropriate treatment, might be fruitful.
authors.affiliation: Amgen, Inc., Thousand Oaks, CA 91320-1789.
authors.forename: C O
authors.initials: CO
authors.lastname: Starnes
mesh_terms: D001428:Bacterial Vaccines / Q000266:history* / Q000627:therapeutic use; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D012509:Sarcoma / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
chemical_list: D001428:Bacterial Vaccines; D014409:Tumor Necrosis Factor-alpha